Aclidinium bromide abrogates allergen-induced hyperresponsiveness and reduces eosinophilia in murine model of airway inflammation

European Journal of Pharmacology

Volumn 649, Issue 1-3, 2010, Pages 349-353

  Damera, Gautam ^a   Jiang, Meiqi ^a   Zhao, Hengjiang ^a   Fogle, Homer W ^a   Jester, William F ^a   Freire, Jose ^b   Panettieri, Reynold A ^a,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b FOREST RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Aclidinium; Airway hyperresponsiveness; Airway inflammation; Asthma

Indexed keywords

ACLIDINIUM BROMIDE; ALLERGEN; INTERLEUKIN 4; INTERLEUKIN 6;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASPERGILLUS FUMIGATUS; ASTHMA; BRONCHODILATING ACTIVITY; CELL COUNT; CELL TYPE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CYTOKINE RELEASE; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; EOSINOPHILIA; FEMALE; LEUKOCYTE MIGRATION; LUNG FUNCTION; LUNG LAVAGE; LUNG RESISTANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIGENS, FUNGAL; ASTHMA; BRONCHITIS; BRONCHOALVEOLAR LAVAGE FLUID; CELL COUNT; CHOLINERGIC ANTAGONISTS; CYTOKINES; FEMALE; INFLAMMATION; LEUKOCYTES; MICE; MICE, INBRED BALB C; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY EOSINOPHILIA; RESPIRATORY HYPERSENSITIVITY; RESPIRATORY SYSTEM; TROPANES;

EID: 78049265848     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.09.043     Document Type: Article

References (39)

1. Alberti J., Martinet A., Sentellas S., Salva M. Enzymatic hydrolysis of aclidinium bromide in human plasma by human esterases. Am. J. Respir. Crit. Care Med. 2009, 179.
2. Barnes P.J. The role of anticholinergics in chronic obstructive pulmonary disease. Am. J. Med. 2004, 117(Suppl 12A):24S-32S.
3. Belmonte K.E. Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2005, 2:297-304. discussion 311-292.
4. Blanchet M.R., Langlois A., Israel-Assayag E., Beaulieu M.J., Ferland C., Laviolette M., Cormier Y. Modulation of eosinophil activation in vitro by a nicotinic receptor agonist. J. Leukoc. Biol. 2007, 81:1245-1251.
5. Bos I.S., Gosens R., Zuidhof A.B., Schaafsma D., Halayko A.J., Meurs H., Zaagsma J. Inhibition of allergen-induced airway remodelling by tiotropium and budesonide: a comparison. Eur. Respir. J. 2007, 30:653-661.
6. Cazzola M., Matera M.G. Novel long-acting bronchodilators for COPD and asthma. Br. J. Pharmacol. 2008, 155:291-299.
7. Corry D.B., Folkesson H.G., Warnock M.L., Erle D.J., Matthay M.A., Wiener-Kronish J.P., Locksley R.M. Interleukin 4, but not interleukin 5 or eosinophils, is required in a murine model of acute airway hyperreactivity. J. Exp. Med. 1996, 183:109-117.
8. Coulson F.R., Fryer A.D. Muscarinic acetylcholine receptors and airway diseases. Pharmacol. Ther. 2003, 98:59-69.
9. Cui Y.Y., Zhu L., Wang H., Advenier C., Chen H.Z., Devillier P. Muscarinic receptors involved in airway vascular leakage induced by experimental gastro-oesophageal reflux. Life Sci. 2008, 82:949-955.
10. Cyphert J.M., Kovarova M., Allen I.C., Hartney J.M., Murphy D.L., Wess J., Koller B.H. Cooperation between mast cells and neurons is essential for antigen-mediated bronchoconstriction. J. Immunol. 2009, 182:7430-7439.
11. Doganci A., Eigenbrod T., Krug N., De Sanctis G.T., Hausding M., Erpenbeck V.J., Haddad el B., Lehr H.A., Schmitt E., Bopp T., Kallen K.J., Herz U., Schmitt S., Luft C., Hecht O., Hohlfeld J.M., Ito H., Nishimoto N., Yoshizaki K., Kishimoto T., Rose-John S., Renz H., Neurath M.F., Galle P.R., Finotto S. The IL-6R alpha chain controls lung CD4+CD25+ Treg development and function during allergic airway inflammation in vivo. J. Clin. Invest. 2005, 115:313-325.
12. Fisher J.T., Vincent S.G., Gomeza J., Yamada M., Wess J. Loss of vagally mediated bradycardia and bronchoconstriction in mice lacking M2 or M3 muscarinic acetylcholine receptors. FASEB J. 2004, 18:711-713.
13. Gavalda A., Calama E., Gomez-Angelats M., Carcasona C., Llenas J., Beleta J., Miralpeix M. In vitro functional profile of aclidinium bromide in isolated guinea pig trachea and left atria. Am. J. Respir. Crit. Care Med. 2009, 179.
14. Gavalda A., Miralpeix M., Ramos I., Otal R., Carreno C., Vinals M., Domenech T., Carcasona C., Reyes B., Vilella D., Gras J., Cortijo J., Morcillo E., Llenas J., Ryder H., Beleta J. Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile. J. Pharmacol. Exp. Ther. 2009, 331:740-751.
15. Gosens R., Zaagsma J., Meurs H., Halayko A.J. Muscarinic receptor signaling in the pathophysiology of asthma and COPD. Respir. Res. 2006, 7:73.
16. Haczku A., Atochina E.N., Tomer Y., Chen H., Scanlon S.T., Russo S., Xu J., Panettieri R.A., Beers M.F. Aspergillus fumigatus-induced allergic airway inflammation alters surfactant homeostasis and lung function in BALB/c mice. Am. J. Respir. Cell Mol. Biol. 2001, 25:45-50.
17. Haczku A., Takeda K., Hamelmann E., Loader J., Joetham A., Redai I., Irvin C.G., Lee J.J., Kikutani H., Conrad D., Gelfand E.W. CD23 exhibits negative regulatory effects on allergic sensitization and airway hyperresponsiveness. Am. J. Respir. Crit. Care Med. 2000, 161:952-960.
18. Hamelmann E., Oshiba A., Loader J., Larsen G.L., Gleich G., Lee J., Gelfand E.W. Antiinterleukin-5 antibody prevents airway hyperresponsiveness in a murine model of airway sensitization. Am. J. Respir. Crit. Care Med. 1997, 155:819-825.
19. Holgate S.T., Roche W.R., Church M.K. The role of the eosinophil in asthma. Am. Rev. Respir. Dis. 1991, 143:S66-S70.
20. Jain D., Keslacy S., Tliba O., Cao Y., Kierstein S., Amin K., Panettieri R.A., Haczku A., Amrani Y. Essential role of IFNbeta and CD38 in TNFalpha-induced airway smooth muscle hyper-responsiveness. Immunobiology 2008, 213:499-509.
21. Kanefsky J., Lenburg M., Hai C.M. Cholinergic receptor and cyclic stretch-mediated inflammatory gene expression in intact ASM. Am. J. Respir. Cell Mol. Biol. 2006, 34:417-425.
22. Kierstein S., Krytska K., Sharma S., Amrani Y., Salmon M., Panettieri R.A., Zangrilli J., Haczku A. Ozone inhalation induces exacerbation of eosinophilic airway inflammation and hyperresponsiveness in allergen-sensitized mice. Allergy 2008, 63:438-446.
23. Klapproth H., Racke K., Wessler I. Acetylcholine and nicotine stimulate the release of granulocyte-macrophage colony stimulating factor from cultured human bronchial epithelial cells. Naunyn-Schmiedebergs Arch. Pharmacol. 1998, 357:472-475.
24. Kleeberger S.R., Hudak B.B. Acute ozone-induced change in airway permeability: role of infiltrating leukocytes. J. Appl. Physiol. 1992, 72:670-676.
25. Kumar R.K., Foster P.S. Modeling allergic asthma in mice: pitfalls and opportunities. Am. J. Respir. Cell Mol. Biol. 2002, 27:267-272.
26. Kurup V.P., Mauze S., Choi H., Seymour B.W., Coffman R.L. A murine model of allergic bronchopulmonary aspergillosis with elevated eosinophils and IgE. J. Immunol. 1992, 148:3783-3788.
27. Mak J.C., Barnes P.J. Autoradiographic visualization of muscarinic receptor subtypes in human and guinea pig lung. Am. Rev. Respir. Dis. 1990, 141:1559-1568.
28. Neveu W.A., Allard J.B., Dienz O., Wargo M.J., Ciliberto G., Whittaker L.A., Rincon M. IL-6 is required for airway mucus production induced by inhaled fungal allergens. J. Immunol. 2009, 183:1732-1738.
29. Papouchado B.G., Chapoval S.P., Marietta E.V., Weiler C.R., David C.S. Cockroach allergen-induced eosinophilic airway inflammation in HLA-DQ/human CD4(+) transgenic mice. J. Immunol. 2001, 167:4627-4634.
30. Profita M., Giorgi R.D., Sala A., Bonanno A., Riccobono L., Mirabella F., Gjomarkaj M., Bonsignore G., Bousquet J., Vignola A.M. Muscarinic receptors, leukotriene B4 production and neutrophilic inflammation in COPD patients. Allergy 2005, 60:1361-1369.
31. Racke K., Matthiesen S. The airway cholinergic system: physiology and pharmacology. Pulm. Pharmacol. Ther. 2004, 17:181-198.
32. Renz H., Enssle K., Lauffer L., Kurrle R., Gelfand E.W. Inhibition of allergen-induced IgE and IgG1 production by soluble IL-4 receptor. Int. Arch. Allergy Immunol. 1995, 106:46-54.
33. Rossoni G., Manfredi B., Razzetti R., Civelli M., Berti F. Positive interaction of the novel beta2-agonist carmoterol and tiotropium bromide in the control of airway changes induced by different challenges in guinea-pigs. Pulm. Pharmacol. Ther. 2007, 20:250-257.
34. Steinke J.W., Borish L. Th2 cytokines and asthma. Interleukin-4: its role in the pathogenesis of asthma, and targeting it for asthma treatment with interleukin-4 receptor antagonists. Respir. Res. 2001, 2:66-70.
35. Tashkin D.P., Littner M., Andrews C.P., Tomlinson L., Rinehart M., Denis-Mize K. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial. Respir. Med. 2008, 102:479-487.
36. van Noord J.A., Aumann J.L., Janssens E., Verhaert J., Smeets J.J., Mueller A., Cornelissen P.J. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006, 129:509-517.
37. Verbout N.G., Lorton J.K., Jacoby D.B., Fryer A.D. Atropine pretreatment enhances airway hyperreactivity in antigen-challenged guinea pigs through an eosinophil-dependent mechanism. Am. J. Physiol. Lung Cell. Mol. Physiol. 2007, 292:L1126-L1135.
38. Wess J. Muscarinic acetylcholine receptor knockout mice: novel phenotypes and clinical implications. Annu. Rev. Pharmacol. Toxicol. 2004, 44:423-450.
39. Wessler I.K., Kirkpatrick C.J. The non-neuronal cholinergic system: an emerging drug target in the airways. Pulm. Pharmacol. Ther. 2001, 14:423-434.